CA
INSY

Cliff Asness’s Insys Therapeutics, Inc. INSY Stock Holding History

Cliff Asness’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,680
Closed -$83K – 2275
2018
Q4 		$83K Buy
+23,680
New +$165K ﹤0.01% 2158
2016
Q1 		– Sell
-34,319
Closed -$983K – 2328
2015
Q4 		$983K Sell
34,319
-22,888
-40% -$634K ﹤0.01% 1581
2015
Q3 		$1.63M Sell
57,207
-3,288
-5% -$121K ﹤0.01% 1223
2015
Q2 		$2.17M Buy
60,495
+9,893
+20% +$308K ﹤0.01% 1149
2015
Q1 		$1.47M Sell
50,602
-12,102
-19% -$320K ﹤0.01% 1247
2014
Q4 		$1.32M Sell
62,704
-16,600
-21% -$328K ﹤0.01% 1521
2014
Q3 		$1.54M Buy
79,304
+600
+0.8% +$9.42K ﹤0.01% 1403
2014
Q2 		$1.23M Buy
78,704
+600
+0.8% +$9.7K ﹤0.01% 1544
2014
Q1 		$1.62M Buy
78,104
+20,714
+36% +$411K ﹤0.01% 1433
2013
Q4 		$741K Buy
+57,390
New +$796K ﹤0.01% 1868

Other funds holding INSY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Cliff Asness's INSY Position: Q1 2019 in Review

Cliff Asness sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 23,680 shares — an estimated $83K sold.

Cliff Asness first reported a position in INSY in Q4 2013 and held it in 10 quarters. The position peaked at $2.17M in Q2 2015. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

  • Cliff Asness reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Cliff Asness sold 23,680 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $83K.
  • Cliff Asness first reported a position in Insys Therapeutics, Inc. in Q4 2013 and held it in 10 quarters.
  • Cliff Asness's Insys Therapeutics, Inc. position peaked at $2.17M in Q2 2015.
  • 98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on AQR Capital Management's 13F filing for Q1 2019, filed 14 May 2019.